A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Sponsor: Alkermes, Inc.
This PHASE3 trial investigates Schizophrenia and is currently completed. Alkermes, Inc. leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
▶ Show 11 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2020 — Oct 2020 [monthly]
Completed PHASE3
-
Nov 2019 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Aug 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2017 — Jan 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .